Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 2618 • 2015 ACR/ARHP Annual Meeting
Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis
Hiroaki Dobashi¹, Tomohiro Kameda¹, Masayuki Inoo², Ikuko Onishi², Noriyuki Kurata², Miharu Izumikawa¹, Yohei Takeuchi³, Shusaku Nakashima¹, Hiromi Shimada¹, Hiroki Ozaki¹, Risa Wakiya¹ and Norimitsu Kadowaki⁴, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Utazu hospital, Kagawa, Japan, ³Internal Medicine Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Kagawa University, Kagawa, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University,, Kagawa, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that is characterized by synovitis and the destruction of articular structures of multiple joints. The goal…
Abstract Number: 2747 • 2015 ACR/ARHP Annual Meeting
Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy
Janet E. Pope¹, Edward C. Keystone², J Carter Thorne³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁴ and Boulos Haraoui⁵, ¹University of Western Ontario, London, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Amgen Canada Inc., Mississauga, ON, Canada, ⁵University of Montreal Hospital Centre, Montreal, QC, Canada
Background/Purpose: The CAnadian Methotrexate and Etanercept Outcome (CAMEO) study, an open-label trial in patients with active rheumatoid arthritis (RA), revealed that patients achieving low disease…
Abstract Number: 2773 • 2015 ACR/ARHP Annual Meeting
Novel Mechanisms of Action for Methotrexate and Doxycycline: Prevention of Protein Adduct Formation and Free Radical Scavenging
Daniel Anderson¹, Michael J. Duryee², Matthew Zimmerman³, Jun Tian³, Cleofes Sarmiento³, Lynell W. Klassen⁴, James R. O'Dell¹, Geoffrey M. Thiele⁵ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Cell Biology and Physiology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Oxidative stress and free radical formation play an important pathogenic role in rheumatoid arthritis (RA) and a number of other inflammatory diseases. Oxidative stress…
Abstract Number: 463 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders
Takayuki Katsuyama¹, Ken-ei Sada¹, Noriko Toyota-Tatebe², Katsue S. Watanabe¹, Toru Kiguchi³ and Jun Wada², ¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ²Department of Medicine and Clinical Science,, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ³Department of Internal Medicine, Chugoku Central Hospital, Fukuyama, Japan
Background/Purpose: Methotrexate (MTX) is known as an anchor drug for the treatment of rheumatoid arthritis (RA), and MTX-associated lymphoproliferative disorders (MTX-LPD) is of current interest.…
Abstract Number: 473 • 2015 ACR/ARHP Annual Meeting
Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis
Leena R Baghdadi^1,2,3, Richard J Woodman², E Michael Shanahan⁴ and Arduino A Mangoni³, ¹Department of Family and Community Medicine, King Saud University, Riyadh, Saudi Arabia, ²Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia, ³Department of Clinical Pharmacology, Flinders University, Adelaide, Australia, ⁴Department of Rheumatology, Flinders University, Adelaide, Australia
Background/Purpose: Methotrexate (MTX) use has been associated with reduced cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA). Although MTX has anti-inflammatory effects, there…
Abstract Number: 538 • 2015 ACR/ARHP Annual Meeting
Multidrug Resistant Lymphocytes of Patients with Rheumatoid Arthritis Are Predictive for DMARD and Glucocorticoid Treatment Response
Jan Piet van Hamburg¹, Sandra M.J. Paulissen², Nadine Davelaar¹, Mieke Hazes³ and Erik Lubberts¹, ¹Rheumatology and Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ²Room Nb-84, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: A large fraction of patients with RA does not respond to treatment with glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs), or becomes resistant in…
Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Gerd Burmester¹, Gurjit S. Kaeley², Arthur Kavanaugh³, Cem Gabay⁴, Daryl MacCarter⁵, Peter Nash⁶, Tsutomu Takeuchi⁷, Anabela Cardoso⁸, Shufang Liu⁹, Hartmut Kupper¹⁰ and Jasmina Kalabic¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of Florida, Jacksonville, FL, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁶Department of Medicine, University of Queensland, Brisbane, Australia, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Torre Oriente, AbbVie, Lisboa, Portugal, ⁹Immunology Development, AbbVie, North Chicago, IL, ¹⁰AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…
Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…
Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Ruediger Mueller¹, Johannes von Kempis¹, Michael H Schiff² and Sarah Haile³, ¹Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland, ²University of Colorado, Denver, CO, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…
Abstract Number: 2032 • 2014 ACR/ARHP Annual Meeting
Psychological Factors Predict Adherence to Methotrexate (MTX) in Rheumatoid Arthritis (RA); Findings from a Systematic Review of Rates, Predictors and Associations with Patient Outcomes
Holly Hope¹, James Bluett^1,2, Kimme Hyrich³, Lis Cordingley⁴ and Suzanne M. Verstappen³, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is a first line therapy for Rheumatoid Arthritis (RA). Treatment response to MTX is not universal, and nonadherence may partially explain poor…
Abstract Number: 2031 • 2014 ACR/ARHP Annual Meeting
Early Adherence to Methotrexate in Rheumatoid Arthritis (RA) Is High: a Prospective Longitudinal Study of New Users
Holly Hope¹, Kimme Hyrich², James Anderson¹, Lis Cordingley³ and Suzanne Verstappen², ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose Methotrexate (MTX) is the recommended first-line DMARD for rheumatoid arthritis (RA) in most countries, however response is not universal. Non-adherence may explain this to…
Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting
Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Frank I Scott¹, Ronac Mamtani¹, Colleen Brensinger¹, Kevin Haynes², Zelma ChiesaFuxench¹, Huifeng Yun³, Jie Zhang⁴, Lang Chen⁵, Fenglong Xie⁶, David Margolis⁷, James D. Lewis² and Jeffrey R. Curtis⁸, ¹University of Pennsylvania, Philadelphia, PA, ²Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁴Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…
Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting
Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
Yasuhide Kanayama¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴, Nobunori Takahashi², Shinya Hirabara⁴ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…
Abstract Number: 1448 • 2014 ACR/ARHP Annual Meeting
A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis
Françoise Fayet¹, Carine Savel¹, Malory Rodere², Bruno Pereira³, Dihya Abdi¹, Marion Couderc Sr.⁴, Sylvain Mathieu⁵, Anne Tournadre⁶, Sandrine Malochet-Guinamand⁶, Martin Soubrier⁷ and Jean Jacques Dubost⁸, ¹Rheumatology, CHU Gabriel-Montpied, Clermont-ferrand, France, ²Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Chu G.Montpied, Clermont Ferrand, France, ⁵Hopital Gabriel Montpied, Clermont Ferrand, France, ⁶Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷COMEDRA trial group, Paris, France, ⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose Methotrexate is the reference treatment for rheumatoid arthritis (RA). It has potentially serious side effects which can be prevented by an improvement in patient’s…
Abstract Number: 1131 • 2014 ACR/ARHP Annual Meeting
Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis
Alla Skapenko¹, Hendrik Schulze-Koops¹, Viswanath Devanarayan², Kenneth Idler³, Feng Hong⁴, Josef Smolen⁵, Arthur Kavanaugh⁶, Hartmut Kupper⁷ and Jeffrey F. Waring³, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Bioresearch Center, Worchester, MA, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶University of California San Diego, La Jolla, CA, ⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: For patients with rheumatoid arthritis (RA) who fail to attain remission or low disease activity after 6 months of methotrexate (MTX) treatment, TNF inhibitors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].